Solasia Pharma KK
9SO
Company Profile
Business description
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors. The group consists of the company, consolidated subsidiary Solasia Medical Information Consulting (Shanghai) Co. Ltd., and a one-equity-method affiliate. The company is a specialty pharmaceutical company established with the purpose of developing and selling oncology drugs in Japan and other Asian countries, China, and South Korea, and has a portfolio of pharmaceutical and medical device products.
Contact
2-11-1 Shibakoen
4th Floor, Sumitomo Real Estate Shiba Park Tower
Minato-ku
Tokyo105-0011
JPNT: +81 358438045
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
179
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,735.93 | 75.33 | -0.96% |
| DAX 40 | 25,085.30 | 286.45 | -1.13% |
| Dow JONES (US) | 52,326.31 | 541.67 | -1.02% |
| FTSE 100 | 10,654.39 | 70.64 | -0.66% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 25,912.60 | 96.26 | -0.37% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,624.78 | 38.65 | -0.50% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |